- Home
- SUI vs ARWR Comparison
SUI vs ARWR Comparison
Compare SUI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUI | ARWR |
|---|---|---|
| Founded | 1975 | 2003 |
| Country | United States | United States |
| Employees | 3614 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.4B |
| IPO Year | 1996 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SUI | ARWR |
|---|---|---|
| Price | $113.77 | $71.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $141.21 | $83.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 1426.76 | 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,306,100,000.00 | $16,142,321.00 |
| Revenue This Year | $5.24 | N/A |
| Revenue Next Year | $5.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $113.18 | $31.46 |
| 52 Week High | $137.85 | $95.49 |
Technical Indicators
Market Signals| Indicator | SUI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 30.09 |
| Support Level | N/A | $60.60 |
| Resistance Level | $125.16 | $71.83 |
| Average True Range (ATR) | 2.04 | 3.92 |
| MACD | -0.45 | -1.77 |
| Stochastic Oscillator | 8.92 | 16.32 |
Price Performance
Historical ComparisonAbout SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities. The company currently owns a portfolio of 455 properties, which includes 295 manufactured housing communities and 160 RV communities. Sun targets owning properties that are desirable as second homes or vacation properties, with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.